MedAssets Beats on Both Top and Bottom Lines
MedAssets (NAS: MDAS) reported earnings on Oct. 30. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), MedAssets beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share increased.
Gross margins dropped, operating margins grew, net margins grew.
MedAssets recorded revenue of $163.4 million. The 15 analysts polled by S&P Capital IQ hoped for a top line of $154.2 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $143.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.32. The 15 earnings estimates compiled by S&P Capital IQ forecast $0.26 per share. GAAP EPS were $0.09 for Q3 against -$0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 78.8%, 60 basis points worse than the prior-year quarter. Operating margin was 17.1%, 630 basis points better than the prior-year quarter. Net margin was 3.3%, 400 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $160.5 million. On the bottom line, the average EPS estimate is $0.27.
Next year's average estimate for revenue is $631.8 million. The average EPS estimate is $1.11.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 63 members out of 76 rating the stock outperform, and 13 members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 21 give MedAssets a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MedAssets is outperform, with an average price target of $17.91.
- Add MedAssets to My Watchlist.
The article MedAssets Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.